Host: Shira Johnson, MD

Guest: Martin R. Berk, MD, FACC

Host Dr. Shira Johnson welcomes Dr. Martin Berk to discuss the key issues and challenges with anticoagulation in reduction of risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation (NVAF). Dr. Berk will also review the clinical safety and efficacy of SAVAYSA® (edoxaban) as a treatment that reduces the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation and for the treatment of deep vein thrombosis and pulmonary embolism following 5 to 10 days of initial parenteral anticoagulation therapy. SAVAYSA should not be used in patients with nonvalvular atrial fibrillation with creatinine clearance >95 mL/min due to the increased risk of ischemic stroke compared to warfarin. Dr. Martin Berk and Dr. Shira Johnson are presenting on behalf of and receiving compensation from Daiichi Sankyo. Inc. The information presented is consistent with FDA guidelines and the program is not CME accredited and may not be used for CME accreditation. This program is intended for healthcare professionals only.